Major companies participated in the American Society of Clinical Oncology and Bio USA
A number of officials from major pharmaceutical and bio companies in Korea will travel to the United States this month.
This is to inform the R&D achievements and seek new business opportunities by attending the world’s largest oncology conference and bio-convention, which is resumed as a face-to-face event after three years.
According to the pharmaceutical and bio industry on the 5th, the ‘American Society of Clinical Oncology (ASCO 2022)’ to be held in Chicago from the 7th to the 7th and the ‘2022 BIO International Convention’ to be held in San Diego from the 13th to the 16th (hereinafter referred to as Bio USA) ), a large number of domestic pharmaceutical and bio companies will participate.
The American Society of Clinical Oncology, which is in its 58th year this year, is the world’s largest cancer society with more than 400 pharmaceutical and bio companies participating.
It is a place to share clinical results of anticancer drugs under development and industry trends.
Due to the COVID-19 pandemic, it was held non-face-to-face, but this year it was converted to a face-to-face event.
In Korea, Yuhan Corporation, Medpacto, Genexine, HLB, Lunit, Vuno, etc. will participate and announce clinical results.
The National Clinical Trial Support Foundation and the Korea Health Industry Development Institute are also participating in the Korea Pavilion to attract domestic clinical trials by multinational pharmaceutical companies.
Bio USA is the world’s largest bio convention hosted by the American Bio Association.
Due to the COVID-19 pandemic, it was held non-face-to-face in 2020 and 2021, but this year, when it is converted to a face-to-face event, about 15,000 people from pharmaceutical and bio companies and related institutions around the world are expected to attend.
Bio USA is not only a stage to announce the competitiveness of each company, but also a place to enter the global market by establishing networks with other companies, researchers, and investors.
Most major domestic pharmaceutical and bio companies will attend, while Samsung Biologics and Celltrion will set up their own booths.
Samsung Biologics plans to promote its biopharmaceutical contract development and manufacturing (CDMO) competitiveness overseas and win new customer orders.
Celltrion also plans to focus on partnering with overseas companies and building networks.
In addition, Lotte Biologics, a member of the Lotte Group that has announced its entry into the bio business, is also known to participate.
Domestic bio companies that do not set up their own booth will find new business opportunities through partnering meetings with multinational pharmaceutical companies and investors.
An official from a company participating in this year’s Bio USA said, “The conference or Bio USA is an important business opportunity for domestic pharmaceutical companies aiming to enter overseas markets and partner with multinational pharmaceutical companies. etc., so we will work hard to build a network.”
/yunhap news
